Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia

Br J Haematol. 1996 Apr;93(1):151-3. doi: 10.1046/j.1365-2141.1996.450989.x.


The humanized CD52 monoclonal antibody Campath-1H was used as first-line therapy in nine patients with progressive chronic lymphocytic leukaemia (CLL). Intravenous (n = 5) or subcutaneous (n = 4) injections (up to 30 mg/inj.) were given three times a week for a maximum of 18 weeks. Three patients achieved a complete remission (CR) and five patients a partial remission (PR) (response rate 89%). CLL cells were cleared from blood in all patients and from the bone marrow in seven patients. The response duration time was 8 + -24+ months. Adverse events were mild except for one patient who developed CMV pneumonitis. All patients developed lymphocytopenia (B and T cells) but other haematological toxicities were negligible. Campath-1H is a highly effective and well-tolerated agent in patients with previously untreated CLL and further studies are warranted.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / administration & dosage*
  • Antigens, CD / therapeutic use
  • Antigens, Neoplasm*
  • CD52 Antigen
  • Drug Administration Schedule
  • Female
  • Glycoproteins*
  • Humans
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Male
  • Middle Aged


  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins